Cardiogenic shock management (ESC guideline recommendations)
Cardiogenic shock management should include rapid correction of the cause, escalation of hemodynamic support when hypotension with hypoperfusion persists, and consideration of short-term mechanical circulatory support (MCS) in selected patients. [1] In patients with acute myocardial infarction (AMI) complicated by cardiogenic shock, immediate coronary angiography and revascularization are recommended. [2]
Initial management priorities
Early management should include immediate assessment for reversible causes and prompt definitive treatment of the underlying mechanism. [1] Short-term MCS may be used as a bridge-to-recovery (BTR), bridge-to-decision (BTD), or bridge-to-bridge (BTB). [1]
Medication selection algorithm
Inotropic agents should be used selectively in cardiogenic shock with SBP <90 mmHg and evidence of hypoperfusion that persists despite standard treatment including fluid challenge. [1] Inotropic agents are not recommended routinely due to safety concerns unless symptomatic hypotension with evidence of hypoperfusion is present. [1] A vasopressor, preferably norepinephrine, may be considered to increase blood pressure and vital organ perfusion. [1] Thromboembolism prophylaxis is recommended in patients not already anticoagulated and without contraindications to anticoagulation. [1]
Monotherapy versus combination therapy
Hemodynamic support frequently requires combined pharmacologic strategies when both hypotension and hypoperfusion persist (inotropic agents for hypoperfusion with hypotension and vasopressors for perfusion support). [1] Unselected MCS use is not supported because high-quality outcome evidence remains scarce. [1]
Key evidence informing ESC recommendations
In AMI complicated by cardiogenic shock, intra-aortic balloon pump (IABP) use after early revascularization did not reduce 30-day or long-term mortality versus optimal medical therapy, supporting the recommendation against routine IABP use in post-MI cardiogenic shock. [2]
Treatment initiation thresholds and device-therapy triggers
Inotropic agent initiation is recommended when SBP <90 mmHg and evidence of hypoperfusion are present and standard treatment including fluid challenge fails. [1] Short-term MCS is recommended to be considered in cardiogenic shock as BTR, BTD, or BTB (Class IIa, Level C). [1] IABP may be considered as BTR, BTD, or BTB, including treatment of the cause of cardiogenic shock (for example, mechanical complication of acute MI) or as a bridge to long-term MCS or transplantation (Class IIb, Level C). [1] IABP is not routinely recommended in post-MI cardiogenic shock (Class III, Level B). [1]
Targets and goals of therapy
The objective of inotropic therapy is improvement of peripheral perfusion and maintenance of end-organ function. [1] The objective of vasopressor therapy is increase of blood pressure and vital organ perfusion. [1]
Common pitfalls to avoid
Inotropic agents should not be used routinely in cardiogenic shock due to safety concerns. [1] IABP should not be used routinely in post-MI cardiogenic shock. [1] Unselected MCS deployment should be avoided in cardiogenic shock due to lack of supportive outcome evidence for unselected use. [1]
ESC recommendations specific to AMI-complicated cardiogenic shock
Immediate coronary angiography and PCI (if feasible) are recommended in patients with acute MI complicated by cardiogenic shock. [2] If coronary anatomy is unsuitable for PCI, emergency CABG is recommended. [2] Routine IABP use is not recommended for cardiogenic shock complicating AMI after early revascularization. [2]